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Introduction
Extraintestinal pathogenic Escherichia coli (ExPEC) are the main 
cause of urinary tract infection (UTI) in dogs, but also play a role in 
other extraintestinal infections [1]. In conjunction with resistance 
to multiple classes of antimicrobial agent, these pathogens pose a 
significant treatment challenge to veterinarians. A trend towards canine 
ExPEC strains developing FQ resistance and expressing a multidrug-
resistant (MDR) phenotype [2,3] has been compounded by the recent 
isolation of E. coli O25b:H4 ST131 from extraintestinal infections in 
dogs [4] and confirmation that ST131 strains from humans and dogs 
appear to be closely related [5]. ST131 has shown recent and rapid 
global dissemination mainly in humans [5-8], but there are now several 
reports of its occurrence in dogs [5,9,10].
The development of FQ resistance is a step-wise process involving 
mutations in the quinolone resistance-determining region (QRDR) of 
the genes that encode DNA gyrase (gyrA/gyrB) and topoisomerase IV 
(parC/parE) [11]. In addition, chromosomally encoded MDR efflux 
pumps [12] and plasmid-mediated resistance genes (qnrA, qnrB, qnrC 
and qnrS as well as aac[6’]-Ib-cr) have been shown to contribute to 
reduced susceptibility [13]. Canine MDR ExPEC isolates exhibiting 
FQ resistance have been associated with nosocomial infections in 
Australian veterinary referral hospitals [14]. These isolates belonged to 
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Abstract
Fluoroquinolones (FQs) are a recommended treatment for Escherichia coli infections in companion animals, 
particularly in cases of resistance to other drug classes. In a retrospective study, 162 canine clinical E. coli isolates, 
obtained from veterinary diagnostic submissions (January 2005 - June 2008), were analyzed for phylogenetic group 
and antibiogram phenotype, using nine antimicrobials and enrofloxacin, ciprofloxacin, moxifloxacin and pradofloxacin 
minimum inhibitory concentrations (MICs), either in the absence or presence of an efflux pump inhibitor. The isolate 
susceptibility distribution was bimodal; a high proportion (141/162;87%) showed a sensitivity equivalent to wild-
type E. coli (enrofloxacin MIC 0.004 - 0.06 µg/mL), while a minority (4/162;2%) showed reduced susceptibility 
(enrofloxacin MICs of 0.125 - 0.5 µg/mL), and the remainder (17/162;10%) yielding enrofloxacin MICs in the high-
level resistance range of ≥16 µg/mL. All FQ-resistant isolates were also multidrug-resistant. The majority of FQ-
sensitive isolates belonged to phylogenetic group B2 (101/162;62%), and the majority of resistant isolates to group 
D (8/17;47%). A single resistant B2 isolate and three FQ-sensitive isolates were identified as ST131. Efflux pump 
activity contributed significantly to MICs for all FQs, except for ciprofloxacin, which may be attributable to its higher 
polarity compared to the other FQs. These findings confirm a low prevalence of FQ resistance in Australian canine 
E. coli isolates. Detection of a high moxifloxacin: low ciprofloxacin MIC efflux-associated phenotype (102/162;63%) 
amongst canine strains may indicate previous exposure to moxifloxacin selective pressure, providing more evidence 
of exchange of E. coli strains between humans and dogs. The presence of sensitive ST131 strains in the isolate 
collection does suggest, however, that resistant ST131 strains could potentially emerge under both human and 
veterinary antimicrobial selection pressure, a risk that could be mitigated by using the most active fluoroquinolone 
(i.e. pradofloxacin in dogs) against wild-type E. coli at mutant prevention concentrations.
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phylogenetic groups D and A, and possessed typical QRDR mutations, 
efflux pump activity and plasmid-mediated quinolone resistance genes 
[15,16].Whilst the majority of more recently isolated FQ-resistant 
(FQr) canine clinical ExPEC from Australia (2007-2009) also were 
identified as phylogenetic group D [17], 10% of isolates corresponded 
to phylogenetic group B2, with the majority identified as virulent MDR 
ExPEC clonal group ST131 [5]. 
The isolation of FQr ST131 strains from extraintestinal infections in 
dogs could be explained by either of two hypotheses operating alone or 
in tandem. These may have originally been sensitive strains of canine 
origin that acquired FQ resistance under veterinary antimicrobial 
selection pressure, or FQ-resistant ST131 strains may have been 
Citation: Platell J, Trott D, Wetzstein H, Leitner M, Cobbold R (2011) Phylogenetic Grouping, Antibiotic Resistance Profile, Fluoroquinolone 
Susceptibility and ST131 Status of Canine Extra intestinal Escherichia Coli Isolated from Submissions to a Veterinary Diagnostic Laboratory 
2005-08. J Veterinar Sci Technol S6:001. doi:10.4172/2157-7579.S6-001
Page 2 of 8
J Veterinar Sci Technolo              Veterinary Clinical Pharmacology                 ISSN: 2157-7579 JVST, an open access journal 
directly transmitted from humans to dogs, as suggested by evidence 
from both basic prevalence [4] and molecular epidemiology studies [5]. 
In order to test these alternative hypotheses, this study retrospectively 
examined a collection of isolates, representing all E. coli obtained from 
cases of extraintestinal infection in dogs, submitted to an Australian 
veterinary diagnostic microbiology laboratory around the time of the 
first reports of FQr ST131 in humans (2005-2008). The isolates were 
antibiogram phenotyped and susceptibility to four FQs determined by 
broth dilution MIC testing in the absence or presence of an efflux pump 
inhibitor. Isolates were phylogenetically grouped and those belonging 
to group B2 subjected to determination of ST131 status. 
Materials and Methods
Bacterial isolates 
All isolates from canine extraintestinal infections in which E. coli 
was considered the primary pathogen (n = 221) were collected from 
Veterinary Science Diagnostic Services, The University of Queensland 
from January 2005 to June 2008 and stored in Brain Heart Infusion 
broth with 20% glycerol at -80°C until tested. Seven isolates were non-
viable upon resuscitation, resulting in a total of 214 isolates. Isolates 
were obtained from samples from 147 dogs sourced from eight 
veterinary clinics in south-east Queensland. Following phylogenetic 
grouping and MIC testing, isolates from the same dog, with the same 
clinical presentation, identical phylogenetic group and antimicrobial 
susceptibility profile were considered repeat isolates and excluded from 
further analysis, leaving a total of 162 isolates for characterization.
Phylogenetic grouping and determination of ST131 status
All isolates underwent PCR-based determination of major 
phylogenetic groups (A, B1, B2 or D) by triplex PCR [18]. The 
phylogenetic group B2 isolates were screened for ST131 status by PCR-
based detection of ST131-specific single-nucleotide polymorphisms 
(SNPs) in the E. coli housekeeping genes mdh (malate dehydrogenase) 
and gyrB (DNA gyrase subunit B) [19] and PCR detection of the region 
of the rfb locus (gene cluster responsible for O-type determination) 
specific for the O25b variant [20]. 
Antimicrobial susceptibility
All isolates underwent disc-diffusion susceptibility testing to nine 
antimicrobial agents: amoxicillin-clavulanic acid (AMC), ampicillin 
(AMP), ceftazadime (CAZ), cephalothin (KF), enrofloxacin (ENR), 
gentamicin (CN), tetracycline (TET), ticarcillin-clavulanic acid (TIM) 
and trimethoprim sulfamethoxazole (SXT), which represented classes 
of drug that are commonly used in companion animal veterinary 
practice. Resistance score was defined as the number of antimicrobials 
to which the isolate showed resistance, with 0.1 added to the resistance 
score for every antimicrobial that showed intermediate susceptibility. 
A resistance score of ≥ 4 was used to identify the strain as MDR. 
Determination of MICs of four FQs: ciprofloxacin (CIP), moxifloxacin 
(MXF), ENR and pradofloxacin (PRA), was performed in duplicate 
by broth microdilution. Results were accepted if duplicate MICs 
were within one dilution each other, with the more resistant result, if 
applicable, included in the analysis. E. coli ATCC 25922 was used as a 
control strain and methods and interpretative criteria were followed in 
accordance with the Clinical Laboratories Standards Institute (CLSI) 
guidelines [21,22], except for PRA, for which a provisional resistance 
breakpoint of 2 µg/mL was assumed [15]. Isolates were considered to 
be wild-type, if the ENR MIC obtained was ≤0.06 µg/mL [23,24], and 
1st or 2nd-step FQr mutants, if the MIC ranged from 0.125 to 0.5 µg/mL. 
Additionally, high-level FQ resistance was defined as an ENR MIC of 
≥16 µg/mL.
Efflux pump inhibitor testing
To evaluate the contribution of efflux pumps to MIC, isolate 
susceptibilities to four FQs (ENR, CIP, MXF and PRA) were tested in 
the presence of 64 µg/mL of L-phenylalanyl-arginyl-β-naphthylamide 
(PAβN; Sigma P 4157) using broth microdilution [21,22], as described 
above.
Chromosomal Mutations in the Quinolone Resistance 
Determining Region (QRDR)
PCR amplification and Illumina sequencing (Applied Biosystems 
Hitachi 3130xI Genetic Analyzer) of the QRDR for the gyrA and parC 
genes was performed on all isolates classified as 1st or 2nd-step mutants, 
as previously described [25,26]. Mutations in the QRDR of each gene 
were determined by comparison to E. coli ATCC 8739.
Statistical methods
Fisher’s exact test was used to determine any significant associations 
between FQ resistance (as indicated by ENR resistance) and 




The 162 isolates were primarily sourced from extraintestinal 
infections occurring in separate dogs (137/162;85%), with a small 
proportion of dogs (10/147;7%) yielding multiple isolates (25/162;15%). 
The isolates were obtained from dogs that presented to eight different 
veterinary hospitals in south-east Queensland, however the majority of 
isolates (148/162;91%) originated from two of these, which were both 
referral hospitals (Clinic 1,75/162;46% and Clinic 2, 73/162;45%). The 
majority of isolates (151/162;93%) were obtained from the urogenital 
tract including urine (n = 140), prostatic fluid (n = 6), the bladder wall 
(n = 2) and uterus (n = 3). The remaining isolates were sourced from 
wound infection (n = 3), liver biopsy (n = 3), peritoneal fluid (n = 1) and 
blood culture (n = 1). Three isolates were from an undefined aspirate. 
E. coli was isolated in pure culture on sheep blood agar and MacConkey 
agar plates for 70% (113/162) of samples and was considered the 
primary (i.e. most numerically dominant) pathogen for the remainder.
Phylogenetic grouping
Phylogenetic group B2 was the most represented group 
(102/162;63%), with approximately equal distribution of group B1 
(25/162;15%) and group D (23/162;14%) and a low prevalence of group 
A (12/162;7%) amongst the isolates (Table 1). 
Disc-diffusion susceptibility and MDR status
Resistance prevalence for each antimicrobial is shown in Figure 
1. Although no antimicrobial agent tested showed complete efficacy 
against all isolates in the study, for ENR (17 isolates resistant; 10%), 
CAZ (15;9%) and CN (5;3%), the prevalence of resistance was ≤10%. 
The prevalence of resistance to SXT (23;14%), TET (27;17%), AMC 
(32;20%), TIM (36;22%), and KF (36;22%) was higher, with the highest 
proportion of isolates showing resistance to AMP (72; 44%) (Figure 
1). When isolates showing intermediate susceptibility were combined 
with the resistant isolate fraction, the prevalence of non-susceptibility 
was greatly increased for AMP (72 resistant + 40 intermediate; 69%), 
KF (36+68;64%), TET (27+31;36%), AMC (32+18;31%) and TIM 
(36+6;26%), but remained low for CN (0+5;3%), CAZ (15+1;10%), 
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ENR (17+2;12%) and SXT (23+2;15%). The mean resistance score was 
1.7, with a median score of 1 (range 0 to 8). Twenty-five isolates (15%) 
showed complete susceptibility to all tested antimicrobials, and 32 
isolates (20%) were classified as MDR. All ENR resistant isolates except 
one qualified as MDR (mean resistance score 6.24; range 1.3 to 8). 
Associations of phylogenetic group with FQ resistance and 
MDR status
Phylogenetic groups A and D contained the majority of isolates 
exhibiting ENR resistance (group A: 5/17;29%, group D: 8/17;47%) 
and only a single group B2 isolate (1/102;1%) exhibited this phenotype 
(Table 1). Only 11% (16/145) of isolates shown to be ENR-sensitive 
qualified as MDR, whereas ENR resistant isolates were much more 
likely to also be MDR (16/17;94%, P = <0.001). Of the MDR isolates, 
the majority belonged to phylogenetic group D (13/32; 41%), whilst 
the prevalence of MDR in the other phylogenetic groups was much 
lower (group B1: 8/32;25%; group B2: 6/32;19%; group A: 5/32;16%). 
Resistant phenotypes amongst group B2 and D isolates classified 
as MDR were varied, though AMC:AMP:CAZ:KF:TIM (5/19) and 
AMC:AMP:KF:ENR:TET:TIM:SXT (3/19) were shared by more than 
a single isolate. The single ENR-resistant group B2 strain had the 
following profile: AMP:KF:ENR:CN. Significant differences in isolate 
proportional distribution across phylogenetic group were evident 
between ENR-resistant/MDR and sensitive isolates (Table 1), with 
a trend towards increased representation for groups A and D and 
decreased representation for group B2 for resistant isolates.
ST131 status
The single ENR-resistant phylogenetic group B2 isolate and 3/101 
(3%) ENR-sensitive group B2 isolates were shown to belong to clonal 
group ST131. Two of these were positive for the O25b rfb variant (one 
ENR-resistant, one ENR-sensitive). The three FQ-sensitive ST131 
isolates had distinct resistance phenotypes (AMP only; AMC only; and 
AMP:KF:TET:TIM). 
MIC determination
Prevalence of resistance by MIC was the same across the four 
tested FQs, with the same 17 isolates classified as FQr by disc diffusion 
also exhibiting resistance on the basis of MIC testing. The remaining 
isolates were fully sensitive (145/162;90%) and no intermediate isolates 
were detected (Figure 2). Most isolates were considered to be wild-type 
(141/162;87%) with just four isolates displaying MICs equivalent to 
1st or 2nd-step FQ-resistant mutants (three isolates with enrofloxacin 
MICs of 0.125 µg/mL and one isolate with a MIC of 0.5 µg/mL). All 
remaining isolates (n = 17) displayed high-level resistance. For the two 
isolates classified as showing intermediate susceptibility to ENR by disc 
diffusion, both were sensitive (ENR MICs of 0.06 µg/mL and 0.5 µg/
mL) on the basis of MIC testing against all four FQs. MIC values were 
the lowest for PRA (MIC median 0.015 µg/mL, range 0.004 to 16 µg/
mL vs. ENR MIC median 0.03 µg/mL, range 0.004 to 512 µg/mL). The 
MIC values for CIP vs. MFX showed a four-fold or greater difference 
in 63% (102/162) of the isolates. The range, MIC50 and MIC90 values for 
the 162 isolates are shown in Table 2.
Efflux pump inhibitor testing
Phenotypic expression of an efflux pump was observed in the 
majority of E. coli isolates (Figure 3). In the presence of an efflux pump 
inhibitor, a ≥4-fold decrease in MIC was seen in 157 (97%) of isolates 
against ENR (range 2 to 64-fold; median 8-fold), 146 (90%) of isolates 
against PRA (range no change to 32-fold; median 8-fold) and 153 
(94%) of isolates against MXF (range no change to 64-fold; median 
8-fold) (Table 2). However, only 30 (19%) isolates showed a decrease 
in CIP MIC in the presence of efflux pump inhibitor (range no change 
to 8-fold; median 2-fold). These efflux phenotypes were consistent for 
both sensitive and resistant isolates, discriminating between CIP and 
the other FQs.
Chromosomal mutations in the QRDR
In two of the four isolates classified as 1st or 2nd-step mutants (ENR 
MICs, 0.125 µg/mL and 0.5 µg/mL), identical FQ resistance-associated 
mutations were detected in the QRDR of gyrA, i.e., gyrA S83L (TCG 
to TTG) compared to E. coli ATCC 8739. The remaining two isolates 
displayed no mutation in the QRDR of gyrA (ENR MICs, 0.125 µg/
mL for both) and none of the four isolates displayed mutations in the 
Table 2: Range, MIC50 and MIC90 for four fluoroquinolones in the presence and absence of efflux pump inhibitor (EPI).
Antimicrobial +/- EPI
Enrofloxacin Ciprofloxacin Moxifloxacin Pradofloxacin
-EPI +EPI -EPI +EPI -EPI +EPI -EPI +EPI
Range  0.004-512 <0.001-32 0.002-256 0.002-128 0.008-128 <0.001-32 0.002-16 <0.001-8 
MIC50 0.03 0.004 0.015 0.008 0.06 0.004 0.015 0.002
MIC90 8 2 8 8 8 1 2 0.25
No of resistant isolates 17 17 17 17 17 10 17 6
Table 1: Phylogenetic grouping of 162 canine clinical E. coli isolates by enrofloxacin sensitivity (top) and MDR status (bottom).
Phylogenetic Group Number of enrofloxacin sensitive isolates (%) Number of enrofloxacin resistant isolates (%) P value (sensitive vs resistant) Total (%)
A 7 (5) 5 (29) 0.004 12 (7)
B1 22 (15) 3 (18) 0.729 25 (15)
B2 101 (70) 1 (6) < 0.001 102 (63)
D 15 (10) 8 (47) 0.001 23 (14)
Total 145 (100) 17 (100) - 162 (100)
Phylogenetic Group Number of non-MDR isolates (%) Number of MDR isolates (%) P value (MDR vs non-MDR) Total (%)
A 7 (5) 5 (16) 0.059 12 (7)
B1 17 (13) 8 (25) 0.102 25 (15)
B2 96 (73) 6 (19) < 0.001 102 (63)
D 10 (8) 13 (41) < 0.001 23 (14)
Total 132 (100) 32 (100) - 162 (100)
Citation: Platell J, Trott D, Wetzstein H, Leitner M, Cobbold R (2011) Phylogenetic Grouping, Antibiotic Resistance Profile, Fluoroquinolone 
Susceptibility and ST131 Status of Canine Extra intestinal Escherichia Coli Isolated from Submissions to a Veterinary Diagnostic Laboratory 
2005-08. J Veterinar Sci Technol S6:001. doi:10.4172/2157-7579.S6-001
Page 4 of 8
J Veterinar Sci Technolo              Veterinary Clinical Pharmacology                 ISSN: 2157-7579 JVST, an open access journal 
registered FQs prescribed in veterinary and human medicine (ENR, 
CIP and MXF).
The findings of this study confirm that the majority of FQ sensitive 
E. coli isolates from extraintestinal infections in Australian dogs 
(102/162;63%) belong to phylogenetic group B2 and the majority of 
FQr isolates to group D. Prior to the global emergence of ST131, similar 
phylogenetic group distributions were observed in both sensitive and 
resistant ExPEC isolates of human origin [27-29]. 
Clonal group ST131, belonging to phylogenetic group B2, became 
recognized initially due to the presence of an extended spectrum 
β-lactamase gene (blaCTX-M-15) and an association with multidrug 
resistance [6-8]. Later, a stronger association to FQ resistance was 
found, particularly outside of Europe [19], indicating FQ resistance 
may have aided the successful dissemination of this clonal group. In 
the present study, only three sensitive canine B2 isolates were identified 
as ST131, together with a single resistant B2 isolate, all isolated in 
the latter part of the study (between 2007 and 2008). These results 
suggest that both sensitive and resistant ST131 strains are circulating 
within the canine population. Only one of the three FQ-sensitive 
ST131 isolates was classified as MDR and all shared a wild-type FQ 
susceptibility phenotype as well as showing susceptibility to SXT. The 
close genetic similarity of Australian human and canine FQr ST131 
isolates, with a high proportion sharing clonal commonality with a 
prominent international ST131 pulsotype [5], indicates the possibility 
of frequent human-dog exchange of ST131 isolates. Whilst humans 
can be considered to be the primary reservoir of FQr ST131 strains 
[30], the finding of FQ-sensitive ST131 strains in dogs, albeit at low 
prevalence, may indicate a role for veterinary antimicrobial selection 
pressure in the emergence of FQr ST131 variants. Studies to determine 
the prevalence of FQ sensitive ST131 strains in the human population 
are also warranted as alternatively, ST131 strains, regardless of their 
sensitivity profile, could be readily transferred between humans and 
dogs. In addition, the sensitive canine ST131 strains identified in the 
present study should be compared with their FQr counterparts as well as 
FQ-sensitive and FQr human ST131 strains to determine phylogenetic 
and pathotypic similarities.
The prevalence of ST131 in E. coli isolate collections from humans 
is only now being fully investigated. Previously, studies have mainly 
focused on collections of ESBL-positive and/or FQr isolates due to their 
positive associations with ST131, and initial data suggested that FQ-
sensitive strains were extremely rare [19]. However, two recent studies 
have provided evidence that FQ-sensitive ST131 isolates may account 
for significant proportions of isolates. Blanco et al. [32] examined 500 
human E. coli isolates from extraintestinal infections, predominately 
from urine, in Spain and found ST131 accounted for 12% (59/500). 
Although the majority of these (41/59;69%) were FQr, nearly a third of 
the isolates (18/59;31%) showed FQ sensitivity. A similar prevalence 
was observed by Gibreel et al. [32] who examined 300 UTI-associated 
human E. coli isolates from England and found ST131 also accounted 
for 12% of the collection (37/300), with 35% (13/37) displaying FQ 
sensitivity. In our canine study the overall ST131 prevalence was 4% 
of the phylogenetic group B2 isolates (2% overall), with the majority 
of isolates (3/4;75%) displaying a FQ-sensitive phenotype. The low 
prevalence of ST131 isolates causing extraintestinal infections in dogs 
supports the hypothesis that humans are the primary reservoir of 
ST131 in Australia, regardless of FQ sensitivity. 
In this study, FQ resistance was identified as a significant marker for 
MDR, which is in agreement with other companion animal [2,33,34] 
and human ExPEC studies [35]. However, our results show that MDR 
Figure 1: Disc diffusion susceptibility results for 162 E. coli isolates against 
nine antimicrobials. AMC, amoxicillin-clavulanic acid; AMP, ampicillin; 
CAZ, ceftazadime; KF, cephalothin; ENR, enrofloxacin; CN, gentamicin; 
TET, tetracycline; TIM, ticarcillin-clavulanic acid and SXT, trimethoprim 
sulfamethoxazole.
Figure 2: MIC of four fluoroquinolones for 162 E. coli isolates.
QRDR of parC. In the presence of PAβN, the two isolates showing no 
QRDR mutations exhibited a 32-fold decrease in ENR MIC (0.125 → 
0.004 µg/mL; efflux only phenotype), whereas those with gyrA S83L 
exhibited only a 4-fold decrease (0.125 → 0.03 µg/mL and 0.5 → 0.125 
µg/mL; efflux plus first step mutant). 
Discussion
Escherichia coli is the primary cause of most UTIs in dogs [1]. The 
recent isolation of virulent FQr phylogenetic group B2-associated E. coli 
O25b:H4 ST131 from extraintestinal infections in dogs in Australia, the 
majority of which were restricted to the urogenital tract [17], followed 
by confirmation that ST131 isolates from both humans and dogs appear 
to be closely related [5], has intensified the issue of FQ resistance in 
both host species. This study had three primary objectives. Firstly, we 
retrospectively examined a collection of canine ExPEC to determine 
if FQ-sensitive variants of ST131 strains were causing extraintestinal 
infections in dogs prior to the first detection of FQr ST131 variants in 
companion animals. Secondly, we determined the prevalence of FQ 
resistance in the isolate collection and its relationship to multidrug 
resistance and phylogenetic grouping. Thirdly, we examined the 
distribution of FQ MIC susceptibilities in the presence or absence of an 
efflux inhibitor to compare the MICs of the third generation veterinary 
FQ, PRA, which has been recently registered in Europe, against other 
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is not necessarily an indicator of FQ resistance, with over 20% of the 
isolate collection classified as MDR, but only 10% as FQr. Therefore, 
although treatment may have failed for many antimicrobial classes, 
FQs may still be an effective treatment choice. We collected clinical 
ExPEC isolates over a three and a half year timespan and the most 
predominant site of isolation was the urogenital tract (93% of cases), 
confirming the importance of E. coli as the major causative agent of 
both simple and complicated cases of UTI in dogs [1] and associated 
urogenital infections [36]. 
A large proportion of veterinary ExPEC isolates from dogs are 
usually resistant to AMP, TET and KF [37] and this was supported 
by the high rate of resistance to these antimicrobial classes (<65% 
susceptibility) in our study. However, the majority of isolates (i.e., >85%) 
were still susceptible to FQs, SXT and CN, which is also consistent with 
other studies [37,38]. It is difficult to compare international data on E. 
coli resistance in companion animals due to the differences in study 
design and data presentation, particularly before the first veterinary 
CLSI guidelines became available in 1999 [39]. However, studies 
have continually shown that FQ susceptibility has remained high 
for companion animal isolates as shown by Cohn et al. [40] (approx. 
482/547;88%), Oluoch et al. [37] (571/652;88%) and Shaheen et al. 
[34,38] (304/376;81%), all showing >80% susceptibility compared to 
90% susceptibility in our isolate collection. Furthermore, the majority 
of isolates characterized in the present study can be considered to be 
wild-type and not likely to possess mutations in the QRDRs of gyrase 
and/or topoisomerase target genes. 
The higher prevalence of FQ susceptibility observed in our 
study may relate to possible overestimations in previous studies as 
isolates from repeat samples from the same animal may have been 
included, since all E. coli isolates were analyzed without reference to 
patient identification, or that our study location was geographically 
restricted with isolates predominantly sourced from two referral 
hospitals. However, as referral hospitals are more likely to treat dogs 
with previous or current history of antimicrobial treatment and/
or underlying refractory illness, the prevalence of resistance to FQs 
would likely be higher than in primary accession practices, resulting in 
lower FQ susceptibility rates. Our findings may also reflect the unique 
epidemiology of FQ resistance in companion animals in Australia, 
given its geographic isolation and the ban on the use of FQs in food-
producing animals. 
As regularly observed in Australian clinical studies involving both 
human [41] and veterinary isolates [42], our canine ExPEC collection 
showed a bimodal distribution of FQ susceptibility, with the majority 
of isolates fully sensitive, very few isolates of intermediate susceptibility 
and a small proportion of isolates displaying high-level resistance. 
Bimodal distribution is of particular interest as this appears to be an 
unusual characteristic particularly of this antimicrobial class. Biomodal 
distribution of this kind will affect both MIC50 and MIC90 values, which 
are regularly used by clinicians when making appropriate antimicrobial 
choices and therefore is of particular note. FQ susceptibility patterns 
were equivalent across all four FQs tested, with 17 isolates showing 
resistance and PRA showing the lowest MICs in both sensitive and 
resistant isolates. Given PRA’s dual targeting features, low mutant 
prevention concentrations [23], reduced mutant selection windows 
[24], favorable pharmacokinetics [43] and the fact that it would 
 
Figure 3: Minimum inhibitory concentrations of four fluoroquinolones with and without efflux pump inhibitor.
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effectively eliminate both wild-type and first-step mutants (87% and 
1.8% of isolates, respectively, characterized in the present study) at 
the recommended dosing, PRA should be used in preference to older 
veterinary FQs for the treatment of canine urinary tract infections [44]. 
However, once resistance to one FQ is identified, it tends to apply to 
most compounds within the class. Although no CLSI guidelines have 
been set for PRA, when a provisional breakpoint of 2 µg/mL was 
applied, all isolates that showed resistance to ENR, CIP and MXF also 
qualified as “resistant” to PRA. 
Fluoroquinolone resistance is conferred through various 
combinations of mechanisms, including mutations in target enzymes, 
reduced expression of outer membrane porins, drug efflux, and 
plasmid-mediated mechanisms [13]. Chromosomal mutations in the 
target enzymes are likely to be present at MICs >0.125 µg/mL and 
can escalate to several (generally two) point mutations in both gyrA 
and parC once the isolate is considered FQr. In the present study, 
sequencing of the QRDRs of gyrA and parC was undertaken for isolates 
considered 1st and 2nd-step mutants in order to clarify the contribution 
of point mutations to FQ resistance. Two out of the four isolates in this 
category showed single mutations in the QRDR of gyrA (S83L) and no 
isolate had a mutation in the QRDR of parC. The low prevalence of 1st 
and 2ndstep mutants amongst our clinical ExPEC strains (2/162;1%) is 
also in agreement with other studies [41,48].
The AcrAB-TolC system is the most common multidrug efflux 
pump possessed by E. coli [45]. It has been hypothesized that the 
evolutionary role of this pump is protection against antagonistic 
environments such as bile salts [34]. Although, the over expression 
of an efflux pump is unable to confer resistance to FQs without other 
resistance mechanisms present [46], the efflux phenotype was observed 
in the majority (>90%) of isolates in the presence of ENR, MXF or PRA, 
but not CIP. 
The unchanged MICs of CIP in the presence of the efflux pump 
inhibitor, PAβN, versus ≥4-fold reductions in MICs observed for ENR, 
MXF and PRA, most likely indicates differential activation of FQ efflux 
systems as well as a significant contribution of efflux in defining the 
actual phenotypes encountered. Overall differences in the chemical 
structures [24] and/or lipophilicity between CIP and ENR, MXF and 
PRA, with lipophilicity being reflected by their octanol:water coefficients 
(Po/w) determined at neutral pH, help to explain this phenomenon. The 
respective log Po/w values amounted to -1.5 for CIP as compared to 
0.36 for ENR [47] and to -1.9 and -1.4 for MXF and PRA, respectively 
[48,49]. Differences in chemical structure and lipophilicity should 
cause activation of distinct separate efflux systems, thus providing 
for the observed phenotypes and the difference in efficacy of PAβN 
between CIP and the other three FQs. Another example for the primary 
role of efflux systems in defining the FQr phenotype, this time in the 
absence of an efflux inhibitor, was the observed low MIC values of CIP 
versus increased MICs (i.e. greater than four-fold) for MXF in several 
studies involving human clinical isolates of E. coli, which, however, 
were left uncommented [50,51,52] , but would indicate the presence 
of a moxifloxacin-specific efflux. Detection of this particular efflux 
phenotype in the majority (63%) of our canine isolates may indicate 
that these isolates had been exposed to MXF selective pressure, thus 
providing further evidence of potential human to dog transmission of 
ExPEC strains. 
In conclusion, this study identified a low prevalence of ST131 
in a canine clinical E. coli isolate collection from Australia, but 
demonstrated the presence of both FQ-sensitive and FQ-resistant 
variants of this B2 clonal group. Whilst humans can be considered to 
be the primary reservoir of FQr ST131, antimicrobial selection pressure 
in the veterinary field could play a role in the emergence of FQr ST131 
strains in dogs. The low prevalence of both FQ resistant and 1st and 2nd 
step mutants showing reduced FQ susceptibility in Australian canine 
ExPEC isolates, and the demonstrated low MICs of pradofloxacin 
support its use compared to other FQs when indicated for canine 
urogenital infections. Differing efflux phenotypes were observed in 
all isolates and contributed to increased FQ MIC for all tested FQs 
apart from CIP, which may be related to its chemical structure and 
octanol:water coefficient. 
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